Moderna delays coronavirus vaccine trial – report

Moderna's shares drastically fall

Shares of Moderna shrank on Thursday as much as 9.4 percent on a report that said the company’s late-stage trial for a potential coronavirus vaccine will be delayed.

The company, which is working with the National Institutes of Health, was expected to begin the third phase of trial, involving 30,000 participants for its vaccine candidate later this month, pending the results from its mid-stage trial.

However, Moderna is now pushing back the expected start date, according to health-care publication STAT News.

The experimental vaccine contains genetic material called messenger RNA, or mRNA. It became the first candidate to enter the first phase of human trial in March.